A Single-center, Randomized, Double-blind, Sponsor Open, Placebo-controlled, Dose-escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIM0278 After Single and Multiple Subcutaneous Injections in Chinese Healthy Subjects
Latest Information Update: 12 Apr 2024
At a glance
- Drugs ALM-223 (Primary)
- Indications Alzheimer's disease; Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Jiangsu Simcere Pharmaceutical
Most Recent Events
- 08 Apr 2024 Planned End Date changed from 31 Dec 2024 to 31 Jul 2025.
- 08 Apr 2024 Planned primary completion date changed from 30 Sep 2024 to 1 May 2025.
- 05 Sep 2023 New trial record